Related Experiment Video
Updated: Jul 9, 2025
09:52
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
13.5K
Ruthenium brachytherapy for iris melanoma
Emilia Zwolin Ska1, Lidia Główka1, Adam Chicheł2
1Department of Ophthalmology, Poznan´ University of Medical Sciences, Poznan´, Poland.
Journal of Contemporary Brachytherapy
|November 29, 2023
Summary
Ruthenium brachytherapy is an effective treatment for iris and iridociliary melanoma, with good long-term visual acuity outcomes and minimal complications. This study confirms its safety and efficacy in managing these ocular tumors.
Area of Science:
- Ophthalmology
- Oncology
- Radiation Therapy
Background:
- Iris and iridociliary melanoma are rare intraocular tumors.
- Brachytherapy, a form of radiation therapy, is a treatment option for these melanomas.
Purpose of the Study:
- To review the long-term outcomes of ruthenium brachytherapy for iris and iridociliary melanoma.
- To assess the safety and efficacy of this treatment modality.
Main Methods:
- Retrospective review of medical records of patients treated between 1999 and 2021.
- Analysis of patient demographics, treatment details, follow-up duration, and clinical outcomes.
Main Results:
- 24 patients (17 women, 7 men) with a median age of 61.5 years were analyzed.
- Ruthenium brachytherapy demonstrated a low recurrence rate (4%) and manageable side effects like cataracts (50%) and intraocular pressure issues (21%).
- Good final visual acuity (≥0.5) was achieved in 67% of patients, with stable or improved vision in a majority of cases.
Conclusions:
- Ruthenium brachytherapy using standard applicators is an effective and safe treatment for iris and iridociliary melanoma.
- Long-term follow-up revealed no significant post-operative complications, supporting its use in clinical practice.
